The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 64 , ISSUE 3 ( July-September, 2022 ) > List of Articles

Original Article

Dyspnea, Obstruction, Smoking, Exacerbation Index, and Chronic Obstructive Pulmonary Disease Test Score: Correlation in Predicting Outcomes in Patients with Chronic Obstructive Pulmonary Disease Exacerbations

Rashmi Mishra, Mradul Kumar Daga, Ishan Rohatgi, Govind Mawari, HS Hira

Keywords : Chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease test, Dyspnea, Obstruction, smoking, and exacerbation index, Global initiative for chronic obstructive lung disease

Citation Information : Mishra R, Daga M K, Rohatgi I, Mawari G, Hira H. Dyspnea, Obstruction, Smoking, Exacerbation Index, and Chronic Obstructive Pulmonary Disease Test Score: Correlation in Predicting Outcomes in Patients with Chronic Obstructive Pulmonary Disease Exacerbations. Indian J Chest Dis Allied Sci 2022; 64 (3):153-159.

DOI: 10.5005/jp-journals-11007-0049

License: CC BY-NC 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Objectives: Chronic obstructive pulmonary disease (COPD) being a disease with systemic consequences necessitate the use of multidimensional indices for a comprehensive assessment of the disease's impact including the future risk of exacerbations and mortality. To study the role of dyspnea, obstruction, smoking, and exacerbation (DOSE) index as a predictor of future disease severity and its correlation with chronic obstructive pulmonary disease test (CAT) score. Measurements and results: A total of 60 inpatients with COPD exacerbations were followed up for 6 months to record the number of exacerbations of COPD. The DOSE index and CAT score were calculated after stabilization within 48 hours of admission, at 1 week, and again at 6 months. The mean difference between DOSE index score at admission and at 1 week was 1.382 ± 0.561 and at admission and at 6 months was 2.15 ± 0.988, both being statistically significant (p < 0.001). A high DOSE index score (≥4) was associated with a greater risk of 2 or more exacerbations [odds ratio (OR), 12 (3.09–46.60) and risk estimate, 3.75 (1.53–9.17)]. For the prediction of exacerbations, the area under the curve (AUC) was larger for the DOSE index (0.854) than the global initiative for chronic obstructive lung disease (GOLD) stage (0.789), p < 0.001 for both. Furthermore, DOSE index correlated significantly with the CAT score, an established health status measure, at all stages of disease severity; at the onset of exacerbation (r = 0.719, p < 0.001), after stabilization at 1 week (r = 0.736, p < 0.001) and at 6 months (r = 0.884, p < 0.001). Conclusion: The DOSE index is a simple, practical multidimensional grading tool for assessing current symptoms, health status, and future risk in COPD and acts as a guide to disease management as its component items can be modified by interventions. Its correlation with CAT, a well-known score is a novel observation, which further corroborates the validity of the DOSE index.

HTML PDF Share
  1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442. DOI: 10.1371/journal.pmed.0030442.
  2. Halbert RJ, Natoli JL, Gano A. et al. Global burden of COPD: Systematic review and meta-analysis. Eur Respir J 2006;28(3):523–532. DOI: 10.1183/09031936.06.00124605.
  3. Pena VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. Chest J 2000;118(4):981–989. DOI: 10.1378/chest.118.4.981.
  4. Tálamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest J 2007;131(1):60–67. DOI: 10.1378/chest.06-1149.
  5. Bhome AB. COPD in India: Iceberg or volcano? J Thorac Dis 2012;4(3):298–309. DOI: 10.3978/j.issn.2072-1439.2012.03.15.
  6. Jindal SK. A field study on follow-up at 10 years of prevalence of chronic obstructive pulmonary disease and peak expiratory flow rate. Indian J Med Res 1993;98:20–26. PMID: 8495985.
  7. Miravitlles M, Murio C, Guerrero T, et al. On behalf of the DAFNE study group: Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 2003;123(3):784–791. DOI: 10.1378/chest.123.3.784.
  8. Miravitlles M, Ferrer M, Pont A, et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: A two-year follow-up study. Thorax 2004;59(5):387–395. DOI: 10.1136/thx.2003.008730.
  9. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19(116):113–118. DOI: 10.1183/09059180.00002610.
  10. Soler J, Sánchez L, Latorre M, et al. The impact of COPD on hospital resources: The specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 2001;37:375–381. DOI: 10.1016/s0300-2896(01)78818-7.
  11. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of chronic airflow limitation: The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145(6):1321–1327. DOI: 10.1164/ajrccm/145.6.1321.
  12. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34(3):648–654. DOI: 10.1183/09031936.00102509.
  13. van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes 2003;1:13. DOI: 10.1186/1477-7525-1-13.
  14. Chavannes NH, Jones RCM, Postma DS, et al. Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria. Prim Care Respir J 2012;21(3):245–246. DOI: 10.4104/pcrj.2012.00066.
  15. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Respirology 2017;22(3):575–601. DOI: 10.1111/resp.13012.
  16. van Dijk WD, van den Bemt L, van den Haak–Rongen S, et al. Multidimensional prognostic indices for use in COPD patient care: A systematic review. Respir Res 2011;12(1):151. DOI: 10.1186/1465-9921-12-151.
  17. Gruffydd–Jones K, Jones MM. NICE guidelines for chronic obstructive pulmonary disease: Implications for primary care. Br J Gen Pract 2011;61(583):91–92. DOI: 10.3399/bjgp11X556182.
  18. Lange P, Marott J, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. Am J Respir Crit Care Med 2012;186(10):975–981. DOI: 10.1164/rccm.201207-1299OC.
  19. de Torres JP, Casanova C, Marín JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014;69(9):799–804. DOI: 10.1136/thoraxjnl-2014-205770.
  20. Han MK, Muellerova H, Curran–Everett D, et al. GOLD 2011 disease severity classification in COPDGene: A prospective cohort study. Lancet Respir Med 2013;1(1):43–50. DOI: 10.1016/S2213-2600(12)70044-9.
  21. Jones R, Donaldson G, Chavannes N, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(12):1189–1195. DOI: 10.1164/rccm.200902-0271OC.
  22. Sundh J, Janson C, Lisspers K, et al. The dyspnoea, obstruction, smoking, exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J 2012;21(3):295–301. DOI: 10.4104/pcrj.2012.00054.
  23. Motegi T, Jones, Ishii T, et al. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis 2013;259–271. DOI: 10.2147/COPD.S42769.
  24. Rolink M, van Dijk W, van den Haak–Rongen S, et al. Using the DOSE index to predict changes in health status of chronic obstructive pulmonary disease patients. Prim Care Respir J 2013;22(2):169–174. DOI: 10.4104/pcrj.2013.00033.
  25. Dayal HH, Khuder S, Sharrar R, et al. Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res 1994;65:161–171. DOI: 10.1006/enrs.1994.1029.
  26. Jindal SK, Aggarwal AN, Gupta D, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012;16(9):1270–1277. DOI: 10.5588/ijtld.12.0005.
  27. Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee, Global strategies for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256–1276. DOI: 10.1164/ajrccm.163.5.2101039.
  28. Wang L, Tao YX, Dong XY, Zhang Q, Zheng H, Zheng YS, Tang XY, Xu JR, Zhao Y. Demographic, health behavioral, and self-management abilities associated with disease severity among patients with chronic obstructive pulmonary disease: An exploratory study. International Journal of Nursing Practice. 2017 Feb;23(1):e12509.
  29. Zhang J, Miller A, Li Y, et al. Comparison of multiple chronic obstructive pulmonary disease (COPD) indices in Chinese COPD patients. Tubercul Respir Dis (Seoul) 2018;81(2):116–122. DOI: 10.4046/trd.2017.0082.
  30. Kerkhof M, Freeman D, Jones R, et al. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis 2015;10:2439. DOI: 10.2147/COPD.S94259.
  31. Jones PW. COPD assessment test: Rationale, development, validation and performance. J COPD 2013;10(2):269–271. DOI: 10.3109/15412555.2013.776920.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.